Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD-1: First-in-human phase I/II study of TPX-0022 in MET-altered advanced solid tumors
CTR20221187Phase 2Active
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elzovantinib in non-small cell lung cancer (NSCLC), gastric cancer (GC), gastroesophageal junction adenocarcinoma and 3 more (3 arms), sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Dose-limiting toxicity rate, Recommended phase II dose and 1 more. Started May 2022; status: active.
02
Drugs
elzovantinib
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction adenocarcinomacolorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221187.